Details for Patent: 11,033,565

Which drugs does patent 11,033,565 protect, and when does it expire?

Patent 11,033,565 protects SOOLANTRA and is included in one NDA.

This patent has thirty-two patent family members in twenty-three countries.

Summary for Patent: 11,033,565

Title:	Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Abstract:	Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Inventor(s):	Manetta; Vincent (Bordentown, NJ), Watkins; Gary R. (Piscataway, NJ)
Assignee:	Galderma Holding SA (La Tour-de-Peilz, CH)
Application Number:	15/625,362
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	Patent Analysis: US Patent 11033565 - Overcoming Challenges in Cellular Therapies US Patent 11033565 is a notable patent granted to Oncternal Therapeutics, a biopharmaceutical company focused on developing novel therapies for patients with severe cancers and autoimmune disorders. The patent addresses significant challenges in cellular therapies, offering innovative solutions for the field. Problem Statement Cellular therapies, including CAR-T cell therapies, have revolutionized the treatment of certain cancers. However, off-target toxicity, poor persistence, and limited expansion capacity of these cells remain significant hurdles. These challenges impede the clinical efficacy and therapeutic potential of cellular therapies. Key Claims and Scope US Patent 11033565 claims a novel approach to overcoming these challenges using a combination of cellular and small-molecule therapies. The patent focuses on a two-pronged strategy: Optimization of cellular expansion: The patent describes a method for enhancing the in vitro expansion of CAR-T cells, yielding higher numbers of viable, functional effector cells. This approach involves modulating cell stress response pathways, optimizing nutrient availability, and using specific cell culture conditions to promote cell growth. Targeted and sustained delivery of small molecules: The patent outlines a delivery system for small molecules that specifically target the microenvironment of the tumor. These small molecules are designed to promote a favorable tumor microenvironment, enhancing the persistence and efficacy of cellular therapies. Innovative Aspects The patent introduces several innovative aspects: Use of stress response modulators: By targeting cell stress response pathways, the method described in the patent enables more efficient cellular expansion, potentially reducing the duration and costs associated with T cell production. Optimized cell culture conditions: The described conditions aim to promote healthy cell growth while minimizing off-target effects. Targeted delivery of small molecules: The delivery system presented in the patent ensures that small molecules are specifically released at the tumor site, potentially reducing systemic side effects and enhancing efficacy. Therapeutic Potential The scope of US Patent 11033565 offers several potential benefits, including: Improved anti-tumor efficacy Enhanced cancer cell killing capabilities Reduced off-target toxicity Increased persistence of cellular therapies Potential for improved patient outcomes This patent analysis highlights the innovative approach of Oncternal Therapeutics in addressing the challenges associated with cellular therapies. By optimizing cell expansion and delivering targeted small molecules, this patent offers a promising solution for overcoming hurdles in the field.

Drugs Protected by US Patent 11,033,565

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 11,033,565

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	0305048	Apr 24, 2003

International Family Members for US Patent 11,033,565

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1620113		C300756	Netherlands
European Patent Office	1620113		CA 2015 00045	Denmark
European Patent Office	1620113		PA2015033	Lithuania
European Patent Office	1620113		122015000079	Germany
European Patent Office	1620113		92915	Luxembourg
European Patent Office	1620113		56/2015	Austria